Arthur L. Caplan, PhD Will Keynote Defined Health’s Therapeutic Insight 2005 Conference; Keynote to address ‘Drug Safety, Blockbusters, Omics and Ethics: Implications for Drug Development and Commercialization’
MILLBURN, N.J., Feb. 17 /PRNewswire/ — Dr. Arthur L. Caplan, PhD will be the keynote speaker at Defined Health and Communitech’s fifth annual Therapeutic Insight Conference. Therapeutic Insight 2005 (“TI2005”) will take place on May 1 – 3, 2005, at the Ritz-Carlton, Boston.
Dr. Caplan is Emmanuel and Robert Hart Professor of Bioethics, Center for Bioethics & Department of Medical Ethics, University of Pennsylvania. He is chair of the Department of Medical Ethics at University of Pennsylvania, in addition to serving as the Trustee Professor and Director of the University’s Center for Bioethics. Dr. Caplan is also a Professor in the Department of Philosophy and in the Department of Psychiatry in the School of Medicine. He is the author or editor of more than twenty books and over 500 papers in refereed journals, has written a weekly newspaper column on bioethics for the Hearst/King Features syndicate and currently writes a regular column on bioethics for MSNBC.com.
Dr. Caplan’s keynote presentation at Therapeutic Insight 2005 is entitled, “Drug Safety, Blockbusters, Omics and Ethics: Implications for Drug Development and Commercialization.” Drug safety is a key issue for the industry, its regulators and the public. Defined Health has asked Dr. Caplan to explore the implications of commercial blockbusters in the context of current clinical trial standards, shareholder expectations and the increasingly realizable potential of pharmacogenomics, physiomics and metabolomics. In the spirit of previous Therapeutic Insight keynote presentations, Dr. Caplan’s observations are expected to lead to a provocative and constructive dialogue around this important issue.
In addition to Dr. Caplan, speakers at Therapeutic Insight 2005 are:
Karen Bernstein, PhD, Chairman and Editor-in-Chief, BioCentury
Michael D. Clayman, MD, Vice President, Lilly Research Laboratories, Eli
Howard Fillit, MD, Executive Director, The Institute for the Study of
Frederick Frank, Vice Chairman and Director, Lehman Brothers
James A. Geraghty, Senior Vice President, Cardiovascular Division,
Thomas D. Giles, MD, Professor of Medicine and Director of Cardiovascular
Research, Louisiana State University Medical School, Department of
Medicine, Cardiovascular Research Laboratory
Robert H. Glassman, MD, Director, Healthcare Investment Banking, M & A
Group, Merrill Lynch
Mitchell H. Gold, MD, President & Chief Executive Officer, Dendreon
George S. Golumbeski, PhD, Vice President Business Development Licensing
& Strategy – Oncology, Novartis Pharmaceuticals Corp.
Thomas Hofstaetter, PhD, Senior Vice President Corporate Business
Development, Wyeth Pharmaceuticals
Tamar D. Howson, Senior Vice President, Corporate & Business Development,
Bristol-Myers Squibb Company
Steven M. Kelsey, MD, FRCP, FRCPath Group Director, Genentech BioOncology
Arthur M. Krieg, MD, Chief Scientific Officer, Coley Pharmaceutical Group
Jonathan S. Leff, Managing Director, Warburg Pincus
Jeremy Levin, PhD, Global Head, Strategic Alliances, Novartis Institutes
Clive A. Meanwell, MD, Chairman & CEO, The Medicines Company
Arlene Morris, President & CEO, Affymax
Paul Nakagaki, PhD, Head of Pharma Research Strategy, Roche
Aileen Nicoletti, PhD, Senior Consultant, Defined Health
Elizabeth Ofili, MD, MPH, FACC, Professor of Medicine, Chief of
Cardiology, and Director, Clinical Research Center, Morehouse School of
Menelas Pangalos, PhD, VP Neurosciences Drug Discovery, Wyeth
Rodney Pearlman, PhD, Co-Founder, President and CEO, Saegis
Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine,
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical
Neal Rosen, MD, PhD, Professor of Medicine, Memorial Sloan Kettering
Edward C. Saltzman, President, Defined Health
Bruce J. Seeley, Sr. Director Commercial Development & Business Unit
Operations, Genentech BioOncology
Thomas Sheehan, Managing Director, Morgan Stanley
Therapeutic Insight 2005 is sponsored by Defined Health, Communitech Market Intelligence and Goodwin Procter LLP. To register, or for more information, please visit http://www.therapeuticinsight.com/, or contact Communitech (914) 245-7764, http://www.cmius.com/, or Defined Health (973) 921- 2850, http://www.definedhealth.com/.
About Defined Health
Founded more than 20 years ago, Defined Health (http://www.definedhealth.com/) is a leading biopharmaceutical business development strategy consulting firm whose clients include a mix of pharma, emerging and specialty pharma, biotech, and healthcare investment companies. Defined Health’s consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D. Defined Health’s clients include more than half of the world’s top 20 pharmaceutical companies.
Ginny E. Llobell
CONTACT: Ginny E. Llobell, Vice President, Defined Health, +1-973-921-2850
Web site: http://www.definedhealth.com/ http://www.therapeuticinsight.com/
COPYRIGHT 2005 PR Newswire Association LLC
COPYRIGHT 2005 Gale Group